How Much Does NMN/NR Cost in Indiana in 2026?

Indiana Cash-Pay Pricing for NMN and NR

The average cash-pay cost for nicotinamide mononucleotide across Indiana retail and compounding pharmacies is $80 per month for a standard 250 mg once-daily oral capsule. This figure reflects 2026 pricing from both brick-and-mortar compounding pharmacies and telehealth-affiliated mail-order services delivering to Indiana addresses.

Nicotinamide riboside (NR), the closely related NAD+ precursor, occupies a different regulatory position. NR is marketed as the branded supplement Niagen and sold over the counter at $40 to $60 per month for 300 mg daily. A 2022 randomized trial by Martens et al. (N=56) demonstrated that NR at 1 to 000 mg daily for 6 weeks raised whole-blood NAD+ by 142% compared to placebo in healthy middle-aged and older adults 1. NMN, by contrast, remains prescription-only when obtained through compounding channels after the FDA's 2022 decision to exclude it from the dietary supplement definition.

Pricing varies by formulation. Sublingual NMN preparations, which bypass first-pass hepatic metabolism, run $90 to $130 monthly from Indiana-licensed 503A pharmacies 2. Intravenous NAD+ infusions (which deliver the end product directly rather than the precursor) cost $250 to $500 per session at Indiana longevity clinics and are not addressed further here.

Why NMN Has No Manufacturer List Price

NMN has no branded pharmaceutical product on the U.S. market. The $0 manufacturer list price reflects this absence. In November 2022, the FDA accepted a New Drug Investigation application for beta-nicotinamide mononucleotide from Metro International Biotech, which triggered the agency's position that NMN could no longer be sold as a dietary supplement under 21 USC 321(ff)(3)(B) 3.

This regulatory action paradoxically made compounded NMN the primary legal access pathway. Indiana residents obtaining NMN do so through one of two routes: a 503A compounding pharmacy filling an individual patient prescription, or a 503B outsourcing facility producing batches without patient-specific prescriptions 4. The Yoshino et al. clinical trial (N=25 postmenopausal women with prediabetes) published in Science demonstrated that 250 mg daily NMN for 10 weeks improved skeletal muscle insulin sensitivity by approximately 25% without significant adverse events 5.

Indiana Medicaid Coverage: Not Covered for Longevity

Indiana Medicaid, administered through managed care organizations including Anthem, CareSource, MDwise, and MHS, does not cover NMN or NR for NAD+ repletion or general longevity purposes. The sole exception pathway involves type 2 diabetes, where some MCOs have approved NAD+ precursor coverage on a case-by-case basis when conventional therapies have failed.

This exclusion aligns with CMS guidance that state Medicaid programs are not required to cover compounded drugs lacking FDA approval for a specific indication 6. Indiana's Healthy Indiana Plan (HIP 2.0) similarly excludes NAD+ precursors from its formulary. A 2023 systematic review by Reiten et al. analyzing 32 human NAD+ precursor trials concluded that while NMN and NR reliably raise circulating NAD+ levels, "hard clinical endpoint data remain insufficient to support broad therapeutic claims" 7.

For patients seeking Medicaid exception requests, the process requires: documented NAD+ deficiency via blood testing, failure of at least two first-line therapies for the underlying condition, and a letter of medical necessity from a prescribing physician citing peer-reviewed evidence. Approval rates for such exceptions remain below 5% based on available MCO data.

Compounded NMN Legality in Indiana

Compounded nicotinamide mononucleotide is legal in Indiana when dispensed by a pharmacy holding a valid Indiana Board of Pharmacy license and operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. Indiana does not impose additional state-level restrictions beyond federal compounding requirements 8.

The practical requirements for legal compounded NMN in Indiana are straightforward. A licensed prescriber (MD, DO, NP, or PA) must write a patient-specific prescription. The compounding pharmacy must use NMN bulk substance from an FDA-registered supplier. The preparation cannot be "essentially a copy" of a commercially available drug product, a condition easily met since no commercial NMN product exists.

Indiana's Board of Pharmacy follows USP 795 and USP 797 standards for non-sterile and sterile compounding respectively 9. NMN oral capsules fall under USP 795 (non-sterile), while injectable NAD+ preparations require USP 797 compliance. Several Indianapolis-area compounding pharmacies and at least three facilities in Fort Wayne, Carmel, and Bloomington actively compound NMN capsules and sublingual tablets.

Telehealth Access to NMN in Indiana

Indiana permits telehealth prescribing of NMN statewide. The Indiana Telehealth Act (IC 25-1-9.5) allows practitioners to prescribe compounded preparations after a synchronous audio-video encounter without requiring a prior in-person visit for non-controlled substances 10.

Telehealth platforms serving Indiana typically charge $99 to $199 for an initial NAD+ optimization consultation, with follow-up visits at $49 to $99 every 3 to 6 months. The total first-year cost combining telehealth visits and compounded NMN averages $1,100 to $1,400 for a standard 250 mg daily protocol. This compares to approximately $960 per year for cash-pay pharmacy NMN alone ($80 times 12 months).

Multiple telehealth longevity platforms now deliver to all 92 Indiana counties. The prescription is sent electronically to a 503A or 503B pharmacy, which ships temperature-controlled NMN directly to the patient. Shipping adds $5 to $15 per month depending on the pharmacy. A Phase II randomized trial by Yi et al. (N=80 healthy adults aged 40 to 65) showed that 300 mg oral NMN daily for 60 days increased blood NAD+ concentration by 38% and improved 6-minute walking distance compared to placebo 11.

Insurance Coverage Options in Indiana

No major Indiana commercial insurance plan covers NMN or NR as of May 2026. This includes Anthem Blue Cross Blue Shield, UnitedHealthcare, Cigna, and Aetna plans sold on the Indiana health insurance marketplace. The reasoning is consistent across payers: NMN lacks FDA approval for any specific indication, and NAD+ optimization is categorized as wellness or longevity rather than treatment of a diagnosed disease.

Health savings accounts (HSAs) and flexible spending accounts (FSAs) represent the most practical insurance-adjacent option for Indiana residents. The IRS permits HSA/FSA reimbursement for compounded medications when prescribed by a licensed provider for a medical condition 12. Patients using NMN for diagnosed conditions such as insulin resistance, chronic fatigue, or age-related NAD+ deficiency documented by lab testing may qualify.

Some Indiana employers with self-funded health plans have begun adding longevity medicine benefits in 2025 and 2026. These plans occasionally cover NAD+ precursors under a broader "metabolic optimization" benefit category. Patients should request a Summary of Benefits and Coverage document and search for compounding pharmacy or longevity medicine provisions.

Finding the Cheapest NMN in Indiana

The lowest-cost pathway to prescription NMN in Indiana combines telehealth prescribing with a high-volume 503B outsourcing facility. This approach yields monthly costs of $50 to $65 for 250 mg oral capsules, approximately 20% to 35% below the $80 average.

Specific cost-reduction strategies include: purchasing 90-day supplies (which typically reduce per-month cost by 10% to 15%), selecting oral capsules over sublingual formulations, and using pharmacies that batch-compound NMN for multiple patients. A double-blind crossover study by Pencina et al. (N=30 overweight adults) found that even the standard 1 to 000 mg daily dose of the related compound NR was well-tolerated, suggesting that the lower 250 mg NMN dose carries minimal safety concerns for cost-conscious patients starting therapy 13.

Patients should verify third-party testing (Certificate of Analysis) from any compounding pharmacy. The FDA has issued warning letters to facilities producing NMN with substandard purity, and price alone should not drive pharmacy selection 14. Indiana patients can verify pharmacy licensure through the Indiana Professional Licensing Agency database.

NAD+ Testing and Monitoring Costs in Indiana

Baseline and follow-up NAD+ blood testing adds to the total cost of NMN therapy. Intracellular NAD+ assays run $149 to $299 through specialty labs, while whole-blood NAD+ measurements are available at $99 to $199. Most prescribers recommend testing at baseline and again at 8 to 12 weeks to confirm NAD+ elevation.

Standard metabolic panels monitoring liver and kidney function during NMN therapy cost $25 to $75 through Indiana laboratory networks. A longitudinal study by Airhart et al. (N=140 healthy volunteers) confirmed that NR supplementation at 100 to 1 to 000 mg daily for 8 weeks produced no clinically significant changes in hepatic or renal biomarkers 15.

The Endocrine Society has not issued formal guidelines on NAD+ precursor monitoring, but clinical consensus recommends comprehensive metabolic panel at baseline and 12 weeks, followed by every 6 months during ongoing therapy 16. Indiana longevity clinics typically bundle initial lab work into their consultation fee, reducing out-of-pocket testing costs by $50 to $100 compared to ordering labs separately.

Discount Programs and Savings Options

No manufacturer savings card exists for NMN because no branded product is marketed. However, several compounding pharmacy networks offer subscription pricing and loyalty discounts to Indiana patients.

Common discount structures include: first-month pricing at $49 to $59 (versus the standard $80), auto-refill discounts of 10% to 15%, and referral credits of $20 to $50 per new patient. Some telehealth platforms bundle the consultation fee into a monthly membership ($129 to $179) that includes the NMN prescription, pharmacy costs, and quarterly provider check-ins.

GoodRx and similar discount card platforms do not cover compounded preparations, making them inapplicable for prescription NMN. The NeedyMeds database lists no patient assistance programs for nicotinamide mononucleotide. Clinical data from Igarashi et al. demonstrated that oral NMN 250 mg daily in healthy men (N=65) was safe and effectively increased NAD+ metabolites in plasma over 12 weeks, supporting the standard dosing that Indiana pharmacies compound 17.

Indiana residents enrolled in Medicare Part D similarly lack coverage for NMN. The Medicare formulary exclusion applies universally to compounded preparations without an FDA-approved indication, regardless of documented clinical benefit or provider attestation of medical necessity.